中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (36): 6674-6678.doi: 10.3969/j.issn.2095-4344.2012.36.005

• 骨髓干细胞 bone marrow stem cells • 上一篇    下一篇

洛伐他汀对尾悬吊大鼠骨量及其骨髓基质干细胞增殖、分化的影响

曹国龙1，王天兵2   

  1. 1唐山市工人医院骨外三科，河北省唐山市 063000；
    2北京大学人民医院创伤骨科，北京市 100044
  • 收稿日期:2011-12-20 修回日期:2012-01-18 出版日期:2012-09-02 发布日期:2012-09-02
  • 通讯作者: 王天兵，博士，主任医师，北京大学人民医院创伤骨科，北京市 100044 wangtianbing@medmail.com.cn
  • 作者简介:曹国龙★，男，1979年生，河北省唐山市人，汉族，2006年华北煤炭医学院毕业，硕士，主治医师，主要从事骨外科临床医疗工作。 caoglcguol@163.com

Effects of lovastatin on bone mass and the differentiation and proliferation of bone marrow stromal cells in tail-suspended rats

Cao Guo-long1, Wang Tian-bing2   

  1. 1Third Department of Orthopedics, Tangshan Workers Hospital, Tangshan 063000, Hebei Province, China;
    2Department of Orthopedics and Traumatology, People’s Hospital of Peking University, Beijing 100044, China
  • Received:2011-12-20 Revised:2012-01-18 Online:2012-09-02 Published:2012-09-02
  • Contact: 王天兵，博士，主任医师，北京大学人民医院创伤骨科，北京市 100044 wangtianbing@medmail.com.cn
  • About author:Cao Guo-long★, Master, Attending physician, Third Department of Orthopedics, Tangshan Workers Hospital, Tangshan 063000, Hebei Province, China caoglcguol@163.com

PDF

313

被引次数

5

摘要：

背景：诸多临床和基础研究均发现他汀类药物具有成骨潜能，但未能完全证实他汀类药物促骨形成的作用。
目的：观察洛伐他汀体内给药对尾悬吊大鼠骨量和骨髓基质干细胞增殖﹑分化的影响，并探讨洛伐他汀防治失重型骨质疏松的作用潜能。
方法：18只雄性SD大鼠随机均分成对照组、尾悬吊组和悬吊给药组。对照组和尾悬吊组每天蒸馏水灌胃；悬吊给药组每天20 mg/kg洛伐他汀灌胃；两悬吊组大鼠后肢离地进行尾部悬吊，4周后处死所有大鼠。
结果与结论：与对照组比较，两悬吊组股骨各段骨密度、小梁相对体积、骨形态发生蛋白2 mRNA表达水平明显降低；骨小梁分离度、骨吸收周长百分数、破骨细胞数、类骨质周长百分数、碱性磷酸酶活性比及碱性磷酸酶mRNA表达水平显著增高；细胞增殖能力各组间差异无显著性意义。说明尾悬吊4周可导致大鼠骨量丢失；洛伐他汀体内给药不能阻止尾悬吊大鼠股骨骨量丢失，给药早期骨髓基质干细胞向成骨分化能力更强。

关键词: 洛伐他汀, 尾悬吊, 骨组织形态计量学, 骨密度, 骨髓基质干细胞, 成骨细胞

Abstract:

BACKGROUND: Many clinical and basic studies have demonstrated that statins has osteogenic potential. However, whether statin can promote bone formation in vivo has not been fully confirmed.
OBJECTIVE: To investigate the effects of lovastatin on bone mass and the differentiation and proliferation of bone marrow stromal cells in tail-suspended rats, and the protective effect of lovastatin on weightlessness-induced osteoporosis.
METHODS: Eighteen male Sprague-Dawley rats were randomly divided into three groups: control group, the tail-suspended group and tail-suspended combined with administration group. The rats in the control group and tail-suspended group were orally administered distilled water per day; rats in the tail-suspended combined with administration group were orally administered 20 mg/kg lovastatin per day; the rats in the two tail-suspended groups were subjected to tail-suspension by making the hindlimbs away from the ground and all animals were sacrificed 4 weeks later.
RESULTS AND CONCLUSION: The bone mineral density, bone volume/trabecular volume and the expression of bone morphogenetic protein 2 mRNA in two tail-suspended groups were significantly lower than those in the control group, while the trabecular separation, percentage of bone resorption perimeter, osteoclast number, percentage of osteoid perimeter and the activity and mRNA expression levels of alkaline phosphatase in the two tail-suspended groups were significantly higher than those in the control group. There was no significant difference in the proliferation of bone marrow stromal cells between every two groups. The rats with tail suspension for 4 weeks showed markedly decreased bone loss. Lovastatin administration in vivo could not prevent tail suspension-induced bone loss, but the ability of osteoblastic differentiation at early phase was increased in tail-suspended rats either with or without lovastatin treatment.

中图分类号: